USCOM LIMITED — Regulatory Filings 2018

May 23, 2018

==> picture [53 x 63] intentionally omitted <==

ASX MEDIA RELEASE

New US IP for Uscom SpiroSonic Devices Multi-path digital ultrasonic spirometry patent

SYDNEY, Australia, Thursday 24[th] May 2018: Uscom Limited (ASX code: UCM) (the Company or Uscom ) has announced the receipt of a notice of allowance from the United States Patent and Trademark Office for its technology central to the Uscom SpiroSonic pulmonary function monitors. The patent is for an “Ultrasonic flow meter including a single transmitting transducer and a pair of receiving transducers”.

The notice of allowance is for the United States Patent Application No. 12/531105 and provides notice to issue a method patent, subject to payment of various fees, within the next three months. The patent will protect Uscom’s SpiroSonic IP rights in the US until 05-12-2028.

The new Uscom method patent describes technology based on digital transit time ultrasound that improves on the current ultrasonic spirometers and provides research quality pulmonary monitoring in the home care or clinical environment. Spirometry is a common method of measuring pulmonary function and has particular applications in the diagnosis and treatment of asthma, COPD, and occupational lung disease (OLD). Patients blow into the device and multiple parameters of lung function are measured and provide clinicians with vital information. Spirometers use various methods with variable reliability and are often difficult to operate and require daily calibration, and so are poorly adopted in clinical use and patient care suffers. While simple turbines are used commonly to approximate flow, ultrasonic devices, based on transit flow time ultrasonic measurements are the current gold standard, and the multi-path ultrasonic method is a further improvement on this method.

Uscom CEO Associate Professor Rob Phillips said: “Our philosophy is to be practice leading, and allowance of our US patent is further recognition of the leadership of our Uscom science. This patent builds corporate value and defends our devices from copy and protects our future revenues. The unique Uscom SpiroSonic devices apply high fidelity ultrasound to improve spirometry and will improve patient adoption and utilisation of this life saving technology. Uscom is currently in the process of seeking regulatory approval for SpiroSonic devices in China (CFDA) and the US (FDA). The devices are already European certified (CE) and being utilised in a number of Euro Grant research projects. Importantly the new Uscom patent can also be applied to industrial applications to improve the accuracy for any fluid flow monitoring including of oil and petroleum.”

The global spirometry market is projected to exceed $1B USD PA by 2022 and is growing at an estimated 10% PA, largely related to the globally increasing incidence of asthma, COPD and OLD, diseases associated with significant mortality and morbidity.

SpiroSonic multi-path ultrasonic spirometers are one of three suites of cardiovascular and pulmonary devices developed and marketed by Uscom Limited. The USCOM 1A cardiac output monitor and the BP+ central blood pressure and vascular health monitor are also Uscom devices in market or in regulatory process for the China and US markets.

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8 66 Clarence Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

==> picture [53 x 63] intentionally omitted <==

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+Reporter , an innovative stand-alone software solution that provides a digital platform to archive patient examinations, trend measure progress over time, analyse pulse pressure waves and generate a summary report.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary SpiroReporter , an innovative stand-alone software solution that provides a digital platform to archive patient examinations, trend measure progress over time, analyse spirometry outputs and generate a summary report.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8 66 Clarence Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au